ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
実験式(ヒル表記法):
C6H10N6O
CAS番号:
分子量:
182.18
NACRES:
NA.85
PubChem Substance ID:
UNSPSC Code:
51102829
EC Number:
224-396-1
MDL number:
Quality Level
form
powder or crystals
solubility
1 M HCl: 50 mg/mL
antibiotic activity spectrum
neoplastics
mode of action
DNA synthesis | interferes
storage temp.
2-8°C
SMILES string
CN(C)\N=N\c1[nH]cnc1C(N)=O
InChI
1S/C6H10N6O/c1-12(2)11-10-6-4(5(7)13)8-3-9-6/h3H,1-2H3,(H2,7,13)(H,8,9)/b11-10+
InChI key
FDKXTQMXEQVLRF-ZHACJKMWSA-N
Application
Dacarbazine is a triazine antineoplastic agent that is used for DNA methylation via formation of methyl adducts. It is used to treat metastatic malignant melanomas and Hodgkin′s when used in combination with other antineoplastic agents.
Biochem/physiol Actions
Dacarbazine is a purine analog of naturally occurring purine precursor 5-amino-1H-imidazole-4-carboxamide (AIC). It is a synthetic triazine antineoplastic agent that exerts cytotoxic effects by acting as an alkylating agent and by inhibiting DNA synthesis and inducing apoptosis. It is known to induce hepatotoxicity in mice. Dacarbazine is not cell cycle-phase specific.
Other Notes
Keep container tightly closed in a dry and well-ventilated place.
Still not finding the right product?
Explore all of our products under ダカルバジン
signalword
Danger
Hazard Classifications
Acute Tox. 4 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Carc. 1B - Eye Irrit. 2 - Muta. 1B - Skin Irrit. 2 - STOT SE 3
target_organs
Respiratory system
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type P3 (EN 143) respirator cartridges
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
D2390-5G: + D2390-BULK: + D2390-250MG: + D2390-VAR: + D2390-100MG: + D2390-1G:
jan
Michiko Horiguchi et al.
The Journal of pharmacology and experimental therapeutics, 333(3), 782-787 (2010-03-24)
O(6)-methylguanine-DNA methyltransferase (MGMT) plays a crucial role in the defense against the alkylating agent-induced cytotoxic lesion O(6)-alkylguanine in DNA. Although a significant circadian variation in MGMT activity has been found in the liver of mice, the exact mechanism of the
Caroline Robert et al.
The Lancet. Oncology, 14(8), 733-740 (2013-06-06)
Patients with metastatic melanoma, 50% of whose tumours harbour a BRAF mutation, have a poor prognosis. Selumetinib, a MEK1/2 inhibitor, has shown antitumour activity in patients with BRAF-mutant melanoma and in preclinical models when combined with chemotherapy. This study was
Masayuki Sanada et al.
Carcinogenesis, 28(12), 2657-2663 (2007-09-21)
O(6)-Methylguanine and O(6)-chloroethylguanine, which are the primary cytotoxic DNA lesions produced by 5-(3,3-dimethyl-1-triazeno)imidazole-4-carboxamide (dacarbazine) and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea (ACNU), respectively, can be repaired by O(6)-methylguanine-DNA methyltransferase (MGMT), coded by the MGMT gene. However, the two types of drugs exhibit different effects on

